Abstract:Spinocerebellar ataxia type 3 (SCA3) is the most common autosomal dominant ataxia worldwide. First targeted gene therapy trials have started, offering the intriguing scenario of preventive treatment. SCA3 is associated with progressive regional brain atrophy that starts before clinical manifestation. We aimed to identify the spatiotemporal progression pattern of brain atrophy of SCA3 with a focus on early disease stages. T1-weighted MRI scans of 300 SCA3 mutation carriers and 317 controls were analyzed. Subtype and Stage Inference (SuStaIn) was used to identify the sequence of volume loss across selected brain regions. We observed one distinct sequence of brain atrophy events in SCA3 without evidence for the existence of alternative cascades. Atrophy started in the most caudal parts of the brainstem. Almost all preataxic SCA3 mutation carriers clustered in the first atrophy stages. Certainty of sequence estimation was highest for early atrophy stages with prominent involvement of the pons and cerebellar white matter. Brain atrophy in SCA3 follows a clear and distinct sequence ascending from the lower brainstem with an early involvement of white matter. Knowledge of this sequence might support the stratification of SCA3 mutation carriers with an imminent clinical onset for early interventions. ### Competing Interest Statement JF received consultancy frees from Vico Therapeutics, unrelated to the present manuscript, and funding from the Advanced Clinician Scientist Programme (ACCENT, funding code 01EO2107, the ACCENT Program is funded by the German Federal Ministry of Education and Research (BMBF)) as well as a fellow of the Hertie Network of Excellence in Clinical Neuroscience. TK is receiving research support from the German Federal Ministry of Education and Research (BMBF) and Servier. ### Funding Statement This publication is an outcome of ESMI, an EU Joint Programme - Neurodegenerative Disease Research (JPND) project (see [www.jpnd.eu][1]). The project is supported through the following funding organisations under the aegis of JPND: Germany, Federal Ministry of Education and Research (BMBF; funding codes 01ED1602A/B); Netherlands, The Netherlands Organisation for Health Research and Development; United Kingdom, Medical Res earch Council (MR/N028767/1). At the US sites this work was in part supported by the National Ataxia Foundation and the National Institute of Neurological Disorders and Stroke (NINDS) grant R01NS080816. The Center for Magnetic Resonance Research is supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) grant P41 EB027061, the Institutional Center Cores for Advanced Neuroimaging award P30 NS076408 and S10 OD017974 grant. JF received consultancy frees from Vico Therapeutics, unrelated to the present manuscript, and funding from the Advanced Clinician Scientist Programme (ACCENT, funding code 01EO2107, the ACCENT Program is funded by the German Federal Ministry of Education and Research (BMBF)) as well as a fellow of the Hertie Network of Excellence in Clinical Neuroscience. TK is receiving research support from the German Federal Ministry of Education and Research (BMBF) and Servier. MCF is funded by Friedreichs research alliance (FARA, USA) and Fundacao de Amparo a pesquisa do Estado de Sao Paulo (grants # 2021/06739-4 and 2013/07559-3). TJRR is funded by Friedreichs research alliance (FARA, USA). No further conflicting interests were disclosed related to this manuscript. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of the University Hospital Bonn gave ethical approval for this work. Ethics committee/IRB of the University of Campinas gave ethical approval for this work. In addition, the ethics committee/IRB of the Xiangya Hospital, Central South University in China (Reference number: 202310206) gave ethical approval for this work. Ethics committee/IRB of the Radboud University Medical Center Nijmegen gave ethical approval for this work. Ethics committee/IRB of the Salpetrier University Hospital Paris gave ethical approval for this work. Ethics committee/IRB of the University Hospital Tuebingen gave ethical approval for this work. Ethics committee/IRB of the UCL London gave ethical approval for this work.Ethics committee/IRB of the University of Minnesota gave ethical approval for this work. Ehtics committee/IRB of the University Hospital Essen gave ethical approval for this work. Ethics committee/IRB of the University Hospital Heidelberg gave ethical approval for this work. Ethics committee/IRB of the University Medical Center Groningen gave ethical approval for this work. Ethics committee/IRB of the Johns Hopkins University School of Medicine, Baltimore, gave ethical approval for this work, as well as the Massachusetts General Hospital. Ethics committee/IRB of the RWTH Aachen gave ethical approval for this work. Ethics committee/IRB of the University of Cantabria gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors. [1]: http://www.jpnd.eu

Factors Influencing Health-Related Quality of Life of Patients with Spinocerebellar Ataxia

To Investigate Olfactory Impairment in Cerebellar Ataxia

Gait characteristics and clinical relevance of hereditary spinocerebellar ataxia on deep learning

Olfactory Impairment in Familial Ataxias.

Sensitivity of Advanced Magnetic Resonance Imaging to Progression over Six Months in Early Spinocerebellar Ataxia

Health-Related Quality of Life in Patients with Inherited Ataxia in Ireland

Clinical and neurophysiological profile of four German families with spinocerebellar ataxia type 14

Multimodal, Longitudinal Profiling of SCA1 Identifies Predictors of Disease Severity and Progression

Longitudinal Changes of Clinical, Imaging, and Fluid Biomarkers in Preataxic and Early Ataxic Spinocerebellar Ataxia Type 2 and 7 Carriers

Clinically Meaningful Magnetic Resonance Endpoints Sensitive to Preataxic Spinocerebellar Ataxia Types 1 and 3

Data-driven brain atrophy staging in spinocerebellar ataxia type 3

Analysis on Health-related Quality of Life of 180 Chinese Patients with Sporadic Creutzfeldt-Jakob Disease

A Neurophysiological and Neuropsychological Approach

The Pattern and Staging of Brain Atrophy in Spinocerebellar Ataxia Type 2 (SCA2): MRI Volumetrics from ENIGMA-Ataxia

Clinical cerebellar neuroscience: cognitive functioning in spinocerebellar ataxias: an update and future directions

Recent advances in understanding dominant spinocerebellar ataxias from clinical and genetic points of view

Genotype-specific spinal cord damage in spinocerebellar ataxias: an ENIGMA-Ataxia study

The Natural History of Spinocerebellar Ataxia Type 3 in Mainland China: A 2-Year Cohort Study.

Polyneuropathy in Patients with Spinocerebellar Ataxias Types 2, 3, and 10: A Systematic Review

Health-related quality of life of adults with spinal muscular atrophy: insights from a nationwide patient registry in Germany

Responsiveness of the Scale for the Assessment and Rating of Ataxia and Natural History in 884 Recessive and Early Onset Ataxia Patients